| BLIS | Basal-like triple-negative breast cancer |
| ccfDNAs | Circulating cell-free DNAs |
| ccfNAs | Circulating cell-free nucleic acids |
| cfDI | Circulating cell-free DNA integrity |
| CTCs | Circulating tumor cells |
| ctDNAs | Circulating cell-free tumor DNAs |
| ctmiRNAs | Circulating cell-free tumor microRNAs |
| ctmRNAs | Circulating cell-free tumor messenger RNAs |
| ctNAs | Circulating cell-free tumor nucleic acids |
| ctncRNAs | Circulating cell-free tumor non-coding RNAs |
| ER+ | Estrogen receptor-positive breast cancer |
| HER2+ | HER2-positive breast cancer |
| HR+ | Hormone receptor-positive breast cancer |
| IM | Immuno modulatory triple-negative breast cancer |
| LAR | Luminal androgen receptor triple-negative breast cancer |
| MAF | Mutant allele frequencies |
| MES | Mesenchymal-like triple-negative breast cancer |
| NAC | Neo-adjuvant chemotherapy |
| PARPi | PARP inhibitor |
| PR+ | Progesterone receptor-positive breast cancer |
| TFx | Tumor fraction of circulating cell-free DNA |
| TNBC | Triple-negative breast cancer |
| tncRNAs | Tumor non-coding RNAs |
| VAF | Variant allele frequencies |